Organization · Venture Capital
NEWTON BIOCAPITAL
Newton Biocapital is a venture capital firm focused on early-stage life sciences companies targeting chronic health conditions, with offices in Brussels and Tokyo. It leverages the research ecosystems of Europe and Japan to identify promising investment opportunities.
Overview
What NEWTON BIOCAPITAL does
What NEWTON BIOCAPITAL is
Newton Biocapital is a venture capital firm focused on early-stage life sciences companies targeting chronic health conditions, with offices in Brussels and Tokyo. It leverages the research ecosystems of Europe and Japan to identify promising investment opportunities.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- March 18, 2026
Official channels
Find NEWTON BIOCAPITAL elsewhere
Open the official website or a supported primary organization account.
Capability profile
NEWTON BIOCAPITAL as a funder
Investment thesis
Newton Biocapital focuses on leveraging innovation in life sciences to develop solutions for chronic health conditions, creating value for patients and investors.
Focus narrative
Newton Biocapital invests in early-stage companies within the life sciences sector, specifically targeting chronic health conditions such as oncology, autoimmune diseases, neurological diseases, metabolic diseases, and genetic diseases. The organization employs a hands-on investment approach, actively participating as board members and supporting portfolio companies in their strategic decisions and clinical programs.
Value beyond capital
Newton Biocapital emphasizes collaboration between the life sciences ecosystems of Europe and Japan, facilitating access to global pharmaceutical networks and optimal exit strategies for its portfolio companies.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 8
Portfolio context
Notable portfolio companies include: SANTERO (developing antibiotics for multi-drug resistant infections), Dim3 (clinical nutrition platform for hospitals), Epics Therapeutics (oncology drugs based on RNA epigenetics), Synergia Medical (neurostimulation devices for epilepsy), Acticor Biotech (treatments for acute thrombotic diseases), Sequana Medical (implantable device for fluid overload), EditForce (DNA/RNA editing technology), and J-Pharma (novel pharmaceuticals targeting specific diseases).
Common questions
What to know about NEWTON BIOCAPITAL
Upseed classifies NEWTON BIOCAPITAL under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 18, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.